<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Several biotechnology and pharmaceutical companies posted notable gains in Thursday's after-hours trading session, driven by corporate updates, clinical milestones, and acquisition speculation.</p><p>China SXT Pharmaceuticals, Inc. (SXTC) climbed 13.6% to $1.42, adding $0.17 after announcing the launch of its Strategic Artificial Intelligence (AI) Insights Initiative. The program is designed to integrate AI-driven analytics into product portfolio planning and market intelligence, reinforcing the company's long-term vision of evolving into a data-informed, innovation-driven modern traditional Chinese medicine (TCM) enterprise.</p><p>Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65, gaining $16.26 after-hours. The rally followed a Financial Times report that Merck is in talks to acquire the company. Earlier in the day, Revolution Medicines closed 5% higher, and momentum accelerated after the company announced that the FDA granted Breakthrough Therapy Designation to zoldonrasib, its RAS(ON) G12D-selective inhibitor. The designation applies to the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC who have previously received anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.</p><p>KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04, up $2.22 after reporting preliminary unaudited global net product revenue results for the fourth quarter and full year ended December 31, 2025. The company also highlighted other operational indicators, fueling investor optimism.</p><p>Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, adding $0.23 despite no fresh news on Thursday. Investors may still be reacting to the company's January 6 corporate update, which outlined key milestones and expected momentum in the development of azenosertib heading into 2026.</p><p>BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81, up $0.53 as of 7:49 PM EST. The move came without any new company-specific announcements, suggesting momentum-driven trading activity.</p><p>Equillium, Inc. (EQ) added 4.4% to $1.18, a $0.05 increase in after-hours trading. No new developments were reported on Thursday, but the stock still attracted modest buying interest.</p><p>Sagimet Biosciences Inc. (SGMT) rose 7.7% to $6.00, gaining $0.43 after announcing plans to present a poster at the upcoming 10th Annual MASH-TAG Conference in Park City, Utah. The presentation will highlight observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 clinical trial of its fatty acid synthase (FASN) inhibitor, denifanstat. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

KALV

SGMT

SXTC

RVMD

<p>Several biotech companies saw significant gains in after-hours trading, driven by corporate updates and acquisition speculation. China SXT Pharmaceuticals (SXTC) rose 13.6% after launching an AI initiative. Revolution Medicines (RVMD) surged 15.1% following reports of Merck's acquisition talks and FDA breakthrough designation for its drug. KalVista Pharmaceuticals (KALV) advanced 14% on positive revenue results. Other notable gainers included Zentalis Pharmaceuticals (ZNTL), BriaCell Therapeutics (BCTX), Equillium (EQ), and Sagimet Biosciences (SGMT), each experiencing increases without major new announcements.</p>

rttnews

KalVista Pharma

Sagimet Biosciences

China SXT Pharmaceuticals

Revolution Medicines

After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally